The arithmetic at Evotec has rarely looked more contradictory. In the first half of 2026, the company’s core drug discovery operations grew at a 28 percent clip, its biologics arm ran at high capacity utilization, and management signed a fresh artificial-intelligence research alliance. Yet the headline numbers tell a far grimmer story: revenue down nearly a fifth, adjusted EBITDA deep in negative territory, and a share price hovering barely above a decade low.
The disconnect comes down to timing — and a growing pile of deferred milestones. Roughly 40 percent of the revenue shortfall Evotec now anticipates for 2026 stems from partnership milestones that have slipped into 2027, the company disclosed alongside its finalized half-year results. Several strategic deals sit in advanced due diligence or term-sheet negotiations, but their financial contributions will arrive later than originally penciled in.
Guidance Gap Widens After July Reset
The half-year report, released after the close of the quarter, largely confirmed what management had flagged in its July profit warning. Group revenue fell 19.2 percent year on year to €300.1 million, while adjusted EBITDA swung to a loss of €42.7 million, compared with a €1.9 million deficit in the prior-year period.
Evotec reaffirmed its revised full-year targets: revenue in the range of €570 million to €610 million, down from the €700 million to €780 million initially projected, and adjusted EBITDA between minus €70 million and minus €105 million, versus the earlier guidance of zero to €40 million. The confirmation suggests management sees no further deterioration ahead, but the margin for error is thin.
The brighter spots sit squarely in the operational core. Net revenue in the Discovery, Preclinical & Translational Development segment, excluding strategic partnerships, advanced roughly 28 percent year on year. Just–Evotec Biologics, the company’s biologics unit, also posted positive operating momentum on strong capacity utilization. The weakness, in other words, is concentrated where Evotec historically generated its most lucrative income: partnership-driven milestone payments.
Should investors sell immediately? Or is it worth buying Evotec?
New Alliance Fails to Move the Needle
That helps explain why the Odyssey Therapeutics collaboration, unveiled just over three weeks ago, has done little for the stock. Under the AI-powered research partnership targeting autoimmune and inflammatory diseases, Evotec stands to receive milestone payments for validated hit series per target. But milestone-dependent revenue is precisely the category now under pressure, and investors have responded with indifference — the shares have shed 2.7 percent since the announcement.
The market’s focus has shifted almost entirely to operating fundamentals. Even the resignation of supervisory board member Camilla Macapili Languille, disclosed around the same time, drew no meaningful reaction from traders.
Evotec points to the fourth quarter of 2026 as the inflection point when commercial activity should begin converting more forcefully into recognized revenue. Until then, shareholders are left waiting on the strategic options review launched in May, which spans portfolio composition, capital structure, and long-term ownership. The Horizon transformation, also initiated in May, aims to consolidate the company’s global footprint from 19 sites to 10 and generate roughly €75 million in annual savings by the end of 2027 — but that program, too, will take time to feed through.
Shares Stuck Near Multi-Year Lows
The market’s verdict is visible in the tape. The stock closed Friday at €3.37, down 0.8 percent on the day. It has lost 38 percent since the start of the year and sits 57 percent below its 52-week high of €7.75, set on November 5, 2025. A new ten-year low of €3.33 was marked on August 21, leaving the current price just 1.2 percent above that watermark. The distance to the 52-week trough of €3.19, touched on July 14, is a mere 5.5 percent.
The central question for investors remains whether the growth in Evotec’s core discovery and biologics operations can offset the partnership revenue shortfall before the restructuring gains full traction. The confirmed guidance provides a framework, but the second half will determine whether the company’s two-speed recovery can converge into a single upward trajectory.
Ad
Evotec Stock: Buy or Sell?! New Evotec Analysis from August 29 delivers the answer:
The latest Evotec figures speak for themselves: Urgent action needed for Evotec investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 29.
Evotec: Buy or sell? Read more here...
